Fundraising Fox
Ampriondx
San Francisco, US · Founded 2007 · Delaware corporation · 37 employees on LinkedIn · 1 known investors
Find your way into Ampriondx
Sign up to see every warm intro you have to Ampriondx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ampriondx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Amprion develops and offers SAAmplify-αSYN, a validated diagnostic test that detects misfolded pathological α-synuclein in cerebrospinal fluid to support the diagnosis of neurodegenerative disorders such as Parkinson's, Lewy body dementia, and Alzheimer's. It serves physicians and researchers seeking biological confirmation of neurodegenerative disease.
Founders & leadership
Ampriondx was founded in 2007 by Russell Lebovitz and Claudio Soto.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$16.7M disclosed across 2 rounds · 2022–2024
▶$5.8MraisedSep 2024 · 7 investors · BiotechnologyRule 506(b)
- Marc ChanDirector
- Russell LebovitzExecutive Officer, Director
- Rahul BhansaliDirector
- Offering amount
- $15M
- Amount sold
- $5.8M
- Proceeds to insiders
- $291.5K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11MraisedJul 2022 · 9 investors · BiotechnologyRule 506(b)
- Claudio SotoDirector
- Marc ChanDirector
- Peter ClintonDirector
- Kenneth LehmanDirector
- Russell LebovitzExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $11M
- Proceeds to insiders
- $550K
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Ampriondx.
Frequently asked questions
- What does Ampriondx do?
- Amprion develops and offers SAAmplify-αSYN, a validated diagnostic test that detects misfolded pathological α-synuclein in cerebrospinal fluid to support the diagnosis of neurodegenerative disorders such as Parkinson's, Lewy body dementia, and Alzheimer's. It serves physicians and researchers seeking biological confirmation of neurodegenerative disease.
- Who founded Ampriondx?
- Ampriondx was founded by Russell Lebovitz, Claudio Soto in 2007.
- Who are Ampriondx's investors?
- Ampriondx's investors include Snatched Ventures.
- How much funding has Ampriondx raised?
- Ampriondx has disclosed $16.7M raised across 2 rounds.
- Where is Ampriondx headquartered?
- Ampriondx is headquartered in San Francisco, US.